Targeting the m6A RNA methyltransferase METTL3 attenuates the development of kidney fibrosis
Experimental & Molecular Medicine · 01.02.2024 · 56 (2) · 355-369
DOI: 10.1038/s12276-024-01159-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental & Molecular Medicine, online erschienen am 01.02.2024. Verfasst von Hae Rim Jung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Kidney, Methyltransferases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kidney fibrosis is a major mechanism underlying chronic kidney disease (CKD). N 6 -methyladenosine (m 6 A) RNA methylation is associated with organ fibrosis. We investigated m 6 A profile alterations and the inhibitory effect of RNA methylation in kidney fibrosis in vitro (TGF-β-treated HK-2 cells) and in vivo (unilateral ureteral obstruction [UUO] mouse model). METTL3-mediated signaling was inhibited using siRNA in vitro or the METTL3-specific inhibitor STM2457 in vivo and in vitro. In HK-2 cells, METTL3 protein levels increased in a dose- and time-dependent manner along with an increase in the cellular m 6 A levels. In the UUO model, METTL3 expression and m 6 A levels were significantly increased. Transcriptomic and m 6 A profiling demonstrated that epithelial-to-mesenchymal transition- and inflammation-related pathways were significantly associated with RNA m 6 A methylation. Genetic and pharmacologic inhibition of METTL3 in HK-2 cells decreased TGF-β-induced fibrotic marker expression. STM2457-induced inhibition of METTL3 attenuated the degree of kidney fibrosis in vivo. Furthermore, METTL3 protein expression was significantly increased in the tissues of CKD patients with diabetic or IgA nephropathy. Therefore, targeting alterations in RNA methylation could be a potential therapeutic strategy for treating kidney fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Medicine Major, Seoul National University College of Medicine, Seoul, Republic of Korea.
- College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.
ORCID-Profile: Seung-Pyo Hong, Jong-Il Kim, Jung Pyo Lee
Zitieren
APA
Jung, H. R., Lee, J., Hong, S. P., Shin, N., Cho, A., Shin, D. J., Choi, J. W., Kim, J. I., Lee, J. P., & Cho, S. Y. (2024). Targeting the m6A RNA methyltransferase METTL3 attenuates the development of kidney fibrosis. Experimental & Molecular Medicine, 56(2), 355-369. https://doi.org/10.1038/s12276-024-01159-5
Vancouver
Jung HR, Lee J, Hong SP, Shin N, Cho A, Shin DJ, et al. Targeting the m6A RNA methyltransferase METTL3 attenuates the development of kidney fibrosis. Experimental & Molecular Medicine. 2024;56(2):355-369. doi:10.1038/s12276-024-01159-5
BibTeX
@article{Jung2024,
author = {Jung, Hae Rim and Lee, Jeonghwan and Hong, Seung-Pyo and Shin, Nayeon and Cho, Ara and Shin, Dong-Jin and Choi, Jin Woo and Kim, Jong-Il and Lee, Jung Pyo and Cho, Sung-Yup},
title = {Targeting the m6A RNA methyltransferase METTL3 attenuates the development of kidney fibrosis},
journal = {Experimental & Molecular Medicine},
year = {2024},
volume = {56},
number = {2},
pages = {355--369},
doi = {10.1038/s12276-024-01159-5}
}
EUVIMED